Home    Back

 117. Syringomyelia
 [ 2 clinical trials,    4 drugs(DrugBank: 0 drug),    0 target gene / 0 target pathway

Searched query = "Syringomyelia"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Search in Page    e.g. "Phase 3", "Not recruiting", "Japan"
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02807142March 201611 June 2018Efficacy Assessment of the Cell Therapy Medicine NC1 in Patients With Post-traumatic SyringomyeliaEfficacy Assessment of the Cell Therapy Medicine NC1 in Patients With Post-traumatic SyringomyeliaPost-Traumatic SyringomyeliaBiological: NC 1 cell therapyPuerta de Hierro University HospitalNot recruiting18 Years70 YearsAll6Phase 2
2EUCTR2015-002383-16-ES19/01/201619 February 2018Evaluate the efficacy of the cell therapy with NC1 medication in patients with post-traumatic syringomyeliaEvaluate the efficacy of the cell therapy with NC1 medication in patients with post-traumatic syringomyeliaTraumatic spinal cord injury, chronically established, associated with syringomyelia and neurological deficit considered irreversible.;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Product Name: Células mesenquimales troncales adultas autólogas de medula ósea expandidas
Product Code: CME-LEM4
Pharmaceutical Form: Suspension for injection
INN or Proposed INN: células mesenquimales troncales adultas autólogas de médula ósea expandidas
Current Sponsor code: CME-LEM4
Concentration unit: U/ml unit(s)/millilitre
Concentration type: equal
Concentration number: 300000000-
Fundación Investigación Biomédica Hospital Universitario Puerta de HierroNot RecruitingFemale: yes
Male: yes
6Phase 2Spain